Top Abstracts with Expert Perspective: Lymphoproliferative disorders (Lymphoma, CLL)
Tracks
-
| Tuesday, April 21, 2026 |
| 2:20 PM - 3:50 PM |
| Hall 1B, Upper Level |
Speaker
Dr Rory Mcculloch
Consultant Haematologist
Gloucestershire Hospitals NHS Foundation Trust
Session Chair
Dr Talha Munir
Consultant Haematologist
St James Hospital Leeds
Optimising MRD-guided treatment to maximise response duration with ibrutinib-venetoclax: analysis from the FLAIR trial
2:20 PM - 2:35 PM
Dr Talha Munir
Consultant Haematologist
St James Hospital Leeds
Pirtobrutinib in Post-cBTKi chronic lymphocytic leukemia/small lymphocytic lymphoma(CLL/SLL):Phase 1/2 BRUIN Study with >5 years Follow-Up
2:35 PM - 2:50 PM
Prof. Kim Linton
Professor
The Christie NHS Foundation Trust, Manchester Cancer Research Centre & Division of Cancer Sciences, Univ of Manchester
Epcoritamab with Rituximab and Lenalidomide (R2) versus R2 for Relapsed or Refractory Follicular Lymphoma
2:50 PM - 3:05 PM
Dr Li Yuan Chan
Research clinical fellow
The Royal Marsden Hospital
Epidemiology and survival characteristics of Marginal Zone Lymphoma in England, 2014-2021: preliminary analysis from UNCOVER.
3:05 PM - 3:20 PM
Dr Simon Rule
Executive Director Haematology, R&D
AstraZeneca
Surovatamig(AZD0486) achieves high MRD-negative complete responses in R/R DLBCL, including post-CD20 TCE and CD19 CAR-T
3:20 PM - 3:35 PM
Dr Will Lavelle
Haematology Registrar
Gloucestershire Hospitals NHS Foundation Trust
TP53 aberrant Mantle Cell Lymphoma: real-world outcomes in 124 patients treated in the United Kingdom
3:35 PM - 3:50 PM
